Fundraising Fox
BrightSpec
Waltham, US · Founded 2012 · Delaware corporation · 26 employees on LinkedIn · 3 known investors
Find your way into BrightSpec
Sign up to see every warm intro you have to BrightSpec
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BrightSpec team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.
Founders & leadership
Board
Investors · 3
How we know: Arboretum Ventures's portfolio page · funding news · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Genoa Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17.1M disclosed across 5 rounds · 2017–2025
▶$3.9MraisedMay 2025 · 7 investors · Other TechnologyRule 506(b)
- Jenny RookeDirector
- Timothy GermannDirector
- David CashDirector
- Walter ColsmanExecutive Officer, Director
- Dan KidleDirector
- Offering amount
- $11.1M
- Amount sold
- $3.9M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedDec 2022 · 24 investors · Other TechnologyRule 506(b)
- Walter ColsmanExecutive Officer, Director
- David CashDirector
- Terry DunlayDirector
- Jenny RookeDirector
- Dan KidleDirector
- Offering amount
- $15M
- Amount sold
- $7.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$825KraisedOct 2021 · 7 investors · Other TechnologyRule 506(b)
- Terry DunlayDirector
- George KastendikeDirector
- Robert CreedenDirector
- David CashDirector
- Walter ColsmanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $825K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedMar 2019 · 5 investors · Other TechnologyRule 506(b)
- ROBERT LLOYDExecutive Officer, Director
- DAVID CASHDirector
- JAFFRAY WOODRIFFDirector
- WALTER COLSMANDirector
- ROBERT CREEDENDirector
- Offering amount
- $2.7M
- Amount sold
- $2.1M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedAug 2017 · 3 investors · Other TechnologyRule 506(b)
- JAFFRAY WOODRIFFDirector
- ROBERT LLOYDExecutive Officer, Director
- THOMAS JONESDirector
- DAVID MCDANIELExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2.8M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as BrightSpec.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.6M |
| U.S. ArmyArmy | Phase II | 2017 | $998.8K |
| National Science Foundation | Phase II | 2016 | $746.1K |
| U.S. ArmyArmy | Phase II | 2015 | $999.2K |
| National Science Foundation | Phase I | 2015 | $149.9K |
| U.S. ArmyArmy | Phase I | 2013 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does BrightSpec do?
- BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.
- Who are BrightSpec's investors?
- BrightSpec's investors include Arboretum Ventures, Genoa Ventures, Medvest Capital.
- How much funding has BrightSpec raised?
- BrightSpec has disclosed $17.1M raised across 5 rounds.
- Where is BrightSpec headquartered?
- BrightSpec is headquartered in Waltham, US.